Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
We are seeking to out-license our innovative Soluleaves range More
The First Line of Therapy in Severe Migraine Attacks More
Novel effective treatment for Fibromyalgia More
4 and 8 mg Ondansetron are under final development using the proprietary RapidFilm drug delivery Technology securing fast dissolution in the oral cavity without the need of water More
Two new compounds having HDAC (histone deacetylase) inhibition capability have shown the effect of inducing re-differentiation of human brain and breast cancer cells both in vitro and in vivo. More
The first pure, immediate release (Tmax in 13,68 min), completely palatable and free from aftertaste diclofenac potassium formulation in drops at 5% available on the market More
A Robarts' Scientist has generated a target-based primary in vitro cell-based screen for evaluating compounds or peptides affecting scar matrix deposition and remodeling during wound repair. More
A novel mixture of traditional Chinese medicines with anti-platelet aggregation and anti-thrombotic activity for both prevention and treatment of cerebral stroke. More
A new veterinary medicinal composition designed to maintain the oxygenic consumption, to restore hydric, electrolytic and energetic status, as well as the blood pH in affected mammals. More
A number of specific PPLs, a group of prenylflavanone compounds, some novel, were isolated, identified and tested at as low as 0.04 μg/mL to be able to increase survival of neural stem cells, to promote neuronal growth with lengthening of neurite More
Your selection
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- Attention-deficit/hyperactivity disorder
- Autism
- Brain injury
- Cerebral palsy
- Cerebrovascular disorders
- Dyslexia
- Emesis
- Encephalitis
- Epilepsy
- Huntington's disease
- Hypersomnia
- Insomnia
- Meningitis, aseptic
- Meningitis, bacterial
- Meningitis, viral
- Migraine
- Myalgic encephalomyelitis
- Narcolepsy
- Neoplastic meningitis
- Nerve regeneration
- Neuropathy, AIDS-related
- Neuropathy, diabetic
- Neuropathy, peripheral
- Neuroprotection
- Premenstrual dysphoric disorder
- Sleep apnea
- Sleep disorders
- Spasticity
- Spinal cord injury
- Stroke
- Tourette's syndrome
- Vertigo
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us